Taipei, Taiwan. June 20, 2017
The Hukui Biotechnology (Chongqing) Corporation, the subsidiary of Hukui Biotechnology Corporation, signed the Cooperation Framework Agreement with the Zhongguancun Medical Engineering Transformation (Chongqing) Center to promote the development of the biotechnology industry. The goal of the Agreement is to create a biotech incubator platform that promotes the smart medical industry focusing on the development of medicine, top-of-the-range medical equipment, testing reagents, and stem-cell technology. Under this collaboration, the Hukui Biotechnology (Chongqing) Corporation is responsible for screening and introducing excellent biotech companies and products to Chongqing. The Zhongguancun Medical Engineering Transformation (Chongqing) Center then helps these companies to establish themselves in Chongqing and apply for licenses. The main goal is to obtain a Category III license for medical equipment granted by the CFDA.
Supported by the China Food and Drug Administration, the Zhongguancun Medical Engineering Transformation Center (the “Center”) was established by the Beijing Food and Drug Administration, the Zhongguancun Management Committee and the Beijing Haidian District Government to provide an integrated technological innovation and start-up incubation chain service for enterprises. The Center was officially opened on January 1, 2016. In December 2016, the Center was designated by the Beijing Municipal Science & Technology Commission as the transformation base for technological achievements of strategic emerging industries conducted in Beijing City. The Zhongguancun Medical Engineering Institute, the International Medical Inspection & Testing Certification Platform, the Clinical Trial Organization Platform, the Investment and Financing Platform for the Pharmaceutical Industry, the Medical Maker Platform, the Medical Technology Trading Platform, the Medical Education and Training Platform, and the International Medical Transformation Platform are all currently established as centers for building full-chain medical technology services consisting of research, clinics, inspection and testing inspection, investment and financing, marketing, and management performed by the government, members of the industry, and academics. The Center has established 8 service platforms to date, including the Medical Engineering Transformation Institute, the Inspection & Testing System Certification Platform, the Pharmaceutical Industry Investment Fund Platform, the Medicine Trading Platform, the Technology and Product Application Platform, the Clinical Trial Resource Platform, the International Technology Exchange Platform, and the Food and Drug Education and Training Platform.
In fulfillment of the Guiding Opinions of the General Office of the State Council on Promoting the Sound Development of the Medical Industry, the Chongqing Municipal Commission of the Economy and Informatization, the Chongqing Liangjiang New-Area Administration Committee and the Zhongguancun Medical Engineering Transformation Center established the Zhongguancun Medical Engineering Transformation (Chongqing) Center. The Center is expected to invest NT$1 billion in its first phase of development. Over the next three years, the Center plans to invest over NT$3 billion. The main function of the Center is to dock policies, technologies, professional services, social capital, markets and international resources, accelerate the transformation of biomedicine and state-of-the-art medical equipment, facilitate the industrialization of advanced medicines and medical equipment, and improve the health of citizens.
Led by honorary Vice Chairman of UMC (NYSE:UMC, TWSE:2303), also Chairman John Hsuan, the Hukui Biotechnology Corporation has established itself as an industrial platform for the biotechnology and big-health industry. The Hukui Biotechnology Corporation provides turnkey services for selected outstanding biotechnology, medical equipment and health companies with products available for sales in markets in China. Three main services provided by the Hukui Biotechnology Corporation include: (1) accelerate in obtaining licenses in China; (2); OEM/ODM production services in factory of Hukui Technology meeting the specifications of the GMP and ISO13485 in China; and (3) strategic cooperation with the largest local medical channel in selling products. Through turnkey services provided by the Hukui Biotechnology Corporation, outstanding biomedical companies around the world can obtain licenses faster, invest at the lower cost, and more efficiently control local marketing channels, allowing them to have stronger competitive advantages in the market.
Both parties have specialties that complement one another. This alliance will strongly attract biomedicine manufacturers and technology proprietors. Located at a key position of the Belt and Road, Chongqing is China’s geographic center and a top priority area in which new businesses settle. Both parties will strive to make Chongqing an excellent gateway for the biomedicine industry in China.
Contact Person: Jeslyn Huang, [email protected] ; +886-2-2579-6538 ext. 12.
